Dyne Therapeutics, Inc. - 8-K Filing
Dyne Therapeutics reported Q2 financial results, $898.5M in cash as of June 30, 2026, with a net loss of $178.6M and announced key clinical/regulatory milestones. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $DYN